Battelle Team Wins DARPA Contract to Build Medical Device to Treat Sepsis
24 Juillet 2013 - 3:58PM
Marketwired
At Battelle, supporting America's military personnel is woven into
the fabric of its business. In that pursuit, a team consisting of
Battelle, NxStage Medical (NASDAQ: NXTM), Inc. and Aethlon Medical
(OTCQB: AEMD) has won a contract from the Defense Advanced Research
Projects Agency, or DARPA, to develop an innovative, new medical
device that may save the lives of soldiers -- and civilians as well
-- by treating sepsis.
The problem to be confronted is more severe than is commonly
known -- as many as 10 percent of combat wounds result in life
threatening infections that ultimately lead to septicemia and/or
sepsis. "This device could not only save many of our soldiers'
lives, it could be profoundly important in saving thousands of
civilian lives each year in the United States alone," said Martin
Toomajian, President of Battelle Energy, Health and
Environment.
DARPA created the Dialysis-Like Therapeutics (DLT) program to
develop a portable device that creates a holistic treatment for
sepsis. The device is intended to remove blood from the body,
separate harmful "dirty" agents from the blood and return "cleaned"
blood to the body in a manner similar to dialysis treatment for
kidney failure. DARPA has made significant investments in its DLT
effort to date to multiple contractors for the development of key
blood purification and diagnostic technologies that could
contribute to the ultimate device.
This contract -- which is funded in phases and could be as large
as $22.83 million and last as long as four years -- is for leading
one of DARPA's DLT System Integration projects. The project calls
for Battelle and key subcontractors, NxStage and Aethlon, to
design, develop, test and validate an advanced, portable medical
device that exhibits the technical innovation for which DARPA
projects are known, and to coordinate integration of key
technologies developed during the overall DLT program. This funding
does not include human clinical trials that may be required prior
to military use and/or United States Food and Drug Administration
clearance for sepsis-treatment technologies.
Beyond the military need for sepsis therapies, the DLT device
may play an important role in saving the lives of civilian
patients, as infection leading to sepsis is a significant cause of
mortality. When sepsis is complicated by shock, approximately half
of patients do not survive for 30 days, even if effective
antibiotics are used.
Because of the interdisciplinary nature of the program, it will
draw experts from many scientific and engineering segments at
Battelle and its development team members. "This program will
utilize a highly diverse set of resources, ranging from medical
device design to biological testing to meeting the exacting needs
of the military-medical environment," said Steve Kelly, President
of Battelle National Security. "Battelle is exceptionally
qualified, together with the collaboration of NxStage and Aethlon,
to bring the necessary diversity of expertise to this complex
program."
Battelle will lead a project team focusing on military user
needs, systems engineering, integration of DLT technologies and
pre-clinical testing. Working closely with Battelle, NxStage will
design, develop and ultimately manufacture and distribute the
medical device upon regulatory approval. Aethlon is developing and
plans to distribute key blood separation component technologies for
the DLT system.
"NxStage is pleased to be chosen as part of this team based upon
our recognized expertise in developing and commercializing
innovative, portable technology for the purification of blood,
which includes use of the System One in the military environment,"
said Jeffrey H. Burbank, Chief Executive Officer of NxStage
Medical, Inc. "We are confident that our leadership in device
design will lead to a good outcome for this important DARPA
project, ultimately benefitting military personnel and civilians
alike."
"We are honored to be part of the DLT System Integration team
and appreciate the continued opportunity to innovate an effective
therapeutic solution to address sepsis," said Aethlon Medical
Chairman and CEO Jim Joyce. Aethlon is the previous recipient of a
$6.8 million DARPA DLT contract.
About Battelle
Every day, the people of Battelle apply science and technology
to solving what matters most. At major technology centers and
national laboratories around the world, Battelle conducts research
and development, designs and manufactures products, and delivers
critical services for government and commercial customers.
Headquartered in Columbus, Ohio since its founding in 1929,
Battelle serves the national security, health and life sciences,
and energy and environmental industries. For more information,
visit www.battelle.org.
About NxStage Medical, Inc.
NxStage is a medical device company, headquartered in Lawrence,
MA, USA, which develops, manufactures, and markets innovative
systems for the treatment of end-stage renal disease (ESRD), and
acute kidney failure. The System One™ home hemodialysis device
developed by NxStage is the only FDA approved portable hemodialysis
machine cleared for home use. For more information on NxStage, or
NxStage® products, visit http://www.nxstage.com.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address
unmet medical needs in cancer, infectious disease, and other
life-threatening conditions. Our Aethlon ADAPT™ System is a
revenue-stage technology platform that provides the basis for a new
class of devices that provide rapid, yet selective removal of
disease promoting particles from the entire circulatory system. At
present, the Aethlon ADAPT™ product pipeline includes the Aethlon
Hemopurifier® to address infectious disease and cancer, and a
medical device being developed under a 5-year contract with Defense
Advanced Research Projects Agency (DARPA) to reduce the incidence
of sepsis in combat-injured soldiers. For more information, please
visit www.aethlonmedical.com.
Add to Digg Bookmark with del.icio.us Add to Newsvine
For more information contact Katy Delaney (614) 424-7208 Email
Contact T.R. Massey (614) 424-5544 Email Contact
Atlas Copco (PK) (USOTC:ATLRF)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Atlas Copco (PK) (USOTC:ATLRF)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024